Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| LycoRed Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to determine if 4-weeks ingestion of LycoRed (code 40051) product containing a mixture of tomato extract with carotenoids and phytochemicals by endurance runners attenuates inflammation, muscle damage and soreness, and oxidative stress during 24 hours recovery from a 2-h running bout.
STUDY DESIGN
STUDY PERFORMANCE
INVESTIGATIONAL PRODUCTS
PRIMARY ENDPOINT
• Oxidative stress biomarkers
SECONDARY ENDPOINTS
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LycoRed (code 40051) product | Experimental | Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks. |
|
| Placebo | Placebo Comparator | Dietary supplement placebo: Only MCT oil. One capsule each day with the morning meal, for 4 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LycoRed (code 40051) product | Dietary Supplement | Mixture of tomato lycopene and carotenoids. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in exercise-induced oxidative stress | F2-isoprostanes. | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Measure | Description | Time Frame |
|---|---|---|
| Change in plasma carotenoids, composite (lycopene, phytofluene, and phytoene) | Indicators of tomato paste product ingestion | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Change in exercise-induced muscle damage marker |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Inability to comply with study requirements.
Any other concurrent condition which, in the opinion of the primary investigator (PI), would preclude participation in this study or interfere with compliance.
Weigh less than 110 pounds.
Current, active history of coronary heart disease, stroke, cancer, diabetes, rheumatoid arthritis, high blood pressure, kidney disease, liver disease, blood disease, hormonal disease, or metabolic disease.
History of cancer in the 5 years prior to the screening visit (except skin or cervical cancer that was successfully treated).
Current use of any type of medication (or unwillingness to stop use of over-the-counter medications two weeks before the start of the study).
Use of any 'recreational substance' whether legal or illegal, by prescription or over the counter.
Pregnant or nursing, or planning to be pregnant or nursing during the study.
Use of vitamin/antioxidant supplements within 4 weeks prior to starting the study. For subjects using vitamin/antioxidant supplements, a 4-week wash out will be required prior to starting the study.
Unwilling to follow dietary guidelines from the screening visit through the final visit as follows:
no more than an average of 2 servings*/week of lycopene-rich foods (e.g. tomatoes and tomato products, including all sauces containing tomatoes that are contained in pizza, soups, etc., ketchup, vegetable juice with tomato, French salad dressing, mango, guava, watermelon, papaya, red grapefruit).
no more than an average of 5 servings*/day of vegetables and fruit
avoidance of antioxidant vitamin, mineral or herbal supplements including, but not limited to vitamin C, vitamin E, flavonoids, carotenoids, selenium, etc.
Consumption of more than an average of 2 units of alcohol daily.**
Known allergy to tomatoes or citrus fruits.
Following any special diet including, but not limited to liquid, high or low protein, raw food, vegetarian or vegan, etc. (Subjects should normally consume mixed diets).
Current use of muscle enhancing supplements such as HMB, ATP and other similar muscle building agents.
Current use of use of sodium bicarbonate or medications containing sodium bicarbonate such as Alka-Seltzer.
Recent history of musculoskeletal trauma (fracture, strain, sprain, etc.) that has not fully healed prior to baseline testing.
Planning to have surgery during the study.
* For the purpose of this study one serving of vegetables or fruit is defined as: Vegetables
1 c raw leafy vegetable; ½ c cut-up raw or cooked vegetable; ½ c vegetable juice Fruit
1 med fruit; ¼ c dried fruit; ½ c fresh, frozen, or canned fruit; ½ c fruit juice
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David C. Nieman, DrPH | Professor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Human Performance Lab, North Carolina Research Campus | Kannapolis | North Carolina | 28081 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25088029 | Result | Ahmed M, Henson DA, Sanderson MC, Nieman DC, Gillitt ND, Lila MA. The protective effects of a polyphenol-enriched protein powder on exercise-induced susceptibility to virus infection. Phytother Res. 2014 Dec;28(12):1829-36. doi: 10.1002/ptr.5208. Epub 2014 Aug 2. | |
| 24760997 | Result | Nieman DC, Shanely RA, Luo B, Meaney MP, Dew DA, Pappan KL. Metabolomics approach to assessing plasma 13- and 9-hydroxy-octadecadienoic acid and linoleic acid metabolite responses to 75-km cycling. Am J Physiol Regul Integr Comp Physiol. 2014 Jul 1;307(1):R68-74. doi: 10.1152/ajpregu.00092.2014. Epub 2014 Apr 23. |
| Label | URL |
|---|---|
| North Carolina Research Campus | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Contains MCT oil. |
|
Creatine kinase |
| baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Change in exercise-induced muscle damage marker | Myoglobin | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Change in exercise-induced inflammation | C-reactive protein | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Change in exercise-induced inflammation, composite | six inflammatory cytokines, MSD panel (plasma IL-6, IL-8, IL-10, TNF-α, G-CSF, MCP-1) | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Change in exercise-induced oxidative stress | Protein carbonyls | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Change in exercise-induced oxidative stress | red blood cell glutathione | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |
| Change in oxidative capacity | FRAP (Ferric Reducing Ability of Plasma) | baseline and 4 weeks/pre-exercise, immediately post-exercise, 1-hour post-exercise, 24-hours post-exercise |